Amylyx Pharmaceuticals (AMLX) Reports Early LUMINA Safety Data, Is The Stock Still Below Fair Value?

Amylyx Pharmaceuticals (AMLX) is back in focus after presenting early Phase 1 LUMINA trial data for its ALS candidate AMX0114 at ENCALS 2026. The company highlighted initial safety findings from the lowest dose cohort.

See our latest analysis for Amylyx Pharmaceuticals.

The LUMINA data arrives during a strong run in Amylyx Pharmaceuticals’ stock, with a 30 day share price return of 27.49%, a year to date share price return of 52.71%, and a 1 year total shareholder return of 168.31%. However, the 3 year total shareholder return is down 16.87%, suggesting recent momentum has picked up after a weaker period.

If this ALS update has you looking more broadly at neurology and biotech, it can be useful to see what else is moving in healthcare focused AI. One place to start is our screener of 39 healthcare AI stocks

With Amylyx Pharmaceuticals now trading at $17.44, sitting at a reported 40% discount to analyst price targets and a 64% gap to an intrinsic estimate, you have to ask: is there real value here, or is the market already pricing in future growth?

Most Popular Narrative: 21.4% Undervalued

Against Amylyx Pharmaceuticals’ last close of $17.44, the most followed narrative points to a fair value of $22.20, implying meaningful upside based on its long term pipeline and PBH opportunity.

The company is targeting post bariatric hypoglycemia, a condition with no FDA approved therapies and an estimated 160,000 patients in the U.S., which creates room for a first approved product like avexitide to establish a new revenue line if pricing and access are secured.

Read the complete narrative.

Curious what underpins that valuation gap? The most followed narrative leans heavily on rapid revenue build, improving margins and a premium future earnings multiple that is far from typical for this sector.

Result: Fair Value of $22.20 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, Amylyx Pharmaceuticals still faces key pressure points, including the single pivotal LUCIDITY readout for avexitide and the potential for future capital needs if development setbacks emerge.

Find out about the key risks to this Amylyx Pharmaceuticals narrative.

Next Steps

Does the mix of optimism and caution around Amylyx Pharmaceuticals resonate with your own view, or raise new questions about risk and reward for this stock? To balance those early concerns with the potential upside and shape your own conclusion, start by reviewing the 2 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Amylyx Pharmaceuticals?

If Amylyx Pharmaceuticals has sharpened your focus, do not stop here. Broaden your watchlist with a few targeted stock ideas that other investors might overlook.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com